I think the excitement is down a bit because everyone thought PRED was going to be 1 of 5. Maybe even 1 of 10. Now it might be 1 of 100 producing a test. Obviously, that will dilute the press coverage significantly as these other CEO’s will be climbing all over each other for coverage. I think PRED may have missed the boat on that big PR jump from being early to the party. However, PRED will still sell every kit it can get. I think the price now reflects the fact that investors understand they possibly won’t see the numbers on sales until August. Even though those numbers are likely to be huge, August is a lifetime away on a stock that gets pummeled by shorts. The hope was that the media spotlight would be put on us and the share price would get to where it needs to be for nasdaq. That now also seems like it will have to wait until August or September when Deloitte puts out some big numbers. There is still time to catch lightening in a bottle but as the days go by the potential jump in share price gets a lower ceiling. Looks like this can go 1 of three ways: 1) FDA approval next few days with massive PR and live happily ever after. 2) No FDA, price steadily drops and then trades sideways as Nasdaq stalls but big numbers in the 10K. This leads to nasdaq in the fall. 3) for some reason, test kits don’t make it here or work well when they do get here in large numbers. If that happens, we are in deep doo doo. The company probably can’t survive that. Number 2 seems the most likely to me as the days go by.
News 
Market Data 
Discover 
